STAT

2018 in limericks: The highs and lows from the life sciences

What a year it's been in the life sciences: CRISPR babies and IPOs galore, high-priced CAR-Ts and gene therapies. We remember it all with the 2018 edition of our year…

It’s been an eventful year in the life sciences, from the struggles of IBM Watson, to China’s twin CRISPR surprise, to a flurry of IPOs, to catching a serial killer with.)

Stai leggendo un'anteprima, registrati per continuare a leggere.

Altro da STAT

STAT1 min lettiMedical
STAT+: Pharmalittle: An Arthritis Drug Reduced Covid-19 Death Rates; Impatience Grows Over Choosing FDA Commissioner
Tocilizumab, a drug usually used to treat rheumatoid arthritis, reduced the rate of death in hospitalized Covid-19 patients in a major clinical trial.
STAT1 min lettiMedical
STAT+: Pharmalittle: FDA Panel Endorses Moderna Covid-19 Vaccine; Sacklers Dodge Blame For Opioid Crisis At Hearing
An FDA advisory panel recommended the agency issue an emergency use authorization for the Moderna Covid-19 vaccine, all but guaranteeing the agency will do so.
STAT1 min lettiMedical
STAT+: Pharmalittle: Pause For J&J Covid-19 Shot To Continue At Least A Week; Biden Expands Candidate List For FDA Commish
The U.S. government pause on use of the Johnson & Johnson Covid-19 vaccine is unlikely to be lifted for at least another week or 10 days.